Mixed dyslipidaemia among patients with metabolic syndrome or diabetes mellitus is very common. Diabetic dyslipidaemia is characterized by increased low-density lipoprotein cholesterol (LDL-C), elevated triglycerides and low high-density lipoprotein cholesterol (HDL-C), is associated with an increased risk of coronary artery disease (CAD). Rosuvastatin in Rosvin- F significantly reduces LDL-C & increase HDL. Fenofibrate reduces triglycerides level and increases HDL level. Thus, the combination of rosuvastatin and fenofibrate offers an improved and effective therapeutic option in the management of diabetic dyslipidemia.
Hypersensitivity to any ingredient of this formulation, Gall bladder disease, Pregnancy and breast feeding. In patients with hepatic or severe renal dysfunction.
Statins with fibrates can cause various muscular side effects including myalgia, myositis; gastrointestinal disturbances, anorexia, headache fatigue, renal impairment, arthralgia have been also reported.
ROSVIN – F is available as a strip of 10 tablets.